Neoadjuvant camrelizumab combined with metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma: a pilot randomized phase 2 trial.

BMC Med · 2026 · PMC13063907 · PMID 41776515

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

did not reach statistical significancep = 0.082so close (0.05 < p ≤ 0.1)

There was a notable disparity in pCR rates between the two groups, with a crude odds ratio (OR) of 6.6 and a 95% confidential interval (CI) ranging from 0.887 to 37.59, though this did not reach statistical significance ( p = 0.082, as shown in Fig. 1 D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.